Results 191 to 200 of about 67,735 (314)

Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer

Molecular Oncology, EarlyView.
We used whole exome and RNA‐sequencing to profile divergent genomic and transcriptomic landscapes of microsatellite stable (MSS) and microsatellite instable (MSI) colorectal cancer. Alterations were classified using a computational score for integrative cancer variant annotation and prioritization.
Efstathios‐Iason Vlachavas, Konstantinos Voutetakis, Vivian Kosmidou, Spyridon Tsikalakis, Spyridon Roditis, Konstantinos Pateas, Ryangguk Kim, Kymberleigh Pagel, Stephan Wolf, Gregor Warsow, Antonia Dimitrakopoulou‐Strauss, Georgios N. Zografos, Alexander Pintzas, Johannes Betge, Olga Papadodima, Stefan Wiemann   +15 more
wiley   +1 more source

Angiotensin-(1-7) receptor Mas is an essential modulator of extracellular matrix protein expression in the heart

, 2012
Elisandra Gava, Carlos H. Castro, Anderson J. Ferreira, H.H.M. Della Colleta, Marcos Barrouin Melo, Natália Alenina, Michael Bäder, Laser Antônio Machado Oliveira, Robson A.S. Santos, Gregory T. Kitten   +9 more
openalex   +1 more source

Angiotensin-(1-7) receptor Mas antagonist (A779) influenced gliosis and reduced synaptic density in the spinal cord after peripheral axotomy

, 2020
Alex Dias Assis, Fernanda Mascarenhas, Fernanda de Assis Araújo, Robson A.S. Santos, Renata Graciele Zanon   +4 more
openalex   +1 more source

Multiplex single‐cell profiling of putative cancer stem cell markers ALDH1, SOX9, SOX2, CD44, CD133 and CD15 in endometrial cancer

Molecular Oncology, EarlyView.
Cancer stem cells are associated with aggressive disease, but a deep characterization of such markers is lacking in endometrial cancer. This study uses imaging mass cytometry to explore putative cancer stem cell markers in endometrial tumors and corresponding organoid models.
Hilde E. Lien, Marta E. Hjelmeland, Hege F. Berg, Rose M. Gold, Kathrine Woie, Lars A. Akslen, Ingfrid S. Haldorsen, Camilla Krakstad   +7 more
wiley   +1 more source

PNA5, A Novel Mas Receptor Agonist, Improves Neurovascular and Blood-Brain-Barrier Function in a Mouse Model of Vascular Cognitive Impairment and Dementia. [PDF]

Aging Dis
Hoyer-Kimura C, Hay M, Konhilas JP, Morrison HW, Methajit M, Strom J, Polt R, Salcedo V, Fricks JP, Kalya A, Pires PW.   +10 more
europepmc   +1 more source

Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection. [PDF]

Front Physiol, 2020
Magalhaes GS, Rodrigues-Machado MDG, Motta-Santos D, Campagnole-Santos MJ, Santos RAS.   +4 more
europepmc   +1 more source

817 AT2 receptor –mediated depressor response to β-Ile5-Ang II in conscious SHR ALSO INVOLVES MAS receptor activation due to β-ile5-ang III

, 2012
Emma S. Jones, Mark Del Borgo, Sanja Bosnyak, Kate M. Denton, Marie‐Isabel Aguilar, Robert E. Widdop   +5 more
openalex   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source

Secreted Monocyte miR-27a, via Mesenteric Arterial Mas Receptor-eNOS Pathway, Causes Hypertension. [PDF]

Am J Hypertens, 2020
Zou X, Wang J, Chen C, Tan X, Huang Y, Jose PA, Yang J, Zeng C.   +7 more
europepmc   +1 more source

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

Molecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh, Amelia Martinez Villarreal, Philippe Lefrançois, Jennifer Gantchev, Sriraam Sivachandran, Samy Abou Setah, Ivan V. Litvinov   +6 more
wiley   +1 more source